Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) for Older Patients With Hematologic Malignancies

Inclusion Criteria

• •Any patient with one of the following hematolymphoid malignancies or syndromes in whom allogeneic hematopoietic stem cell transplant (HST) is warranted. Specific disease categories include:
• •* Indolent advanced stage non-Hodgkin lymphomas
• •* Mantle cell lymphoma
• •* Chronic lymphocytic leukemia
• •* Hodgkin disease (Hodgkin's lymphoma)
• •* Acute leukemias in complete remission
• •* Aplastic anemia
• •* Paroxysmal nocturnal hemoglobinuria
• •* Myelodysplastic or myeloproliferative syndromes.
• •* Other selected malignancies/disorders may also be considered but must be approved by the transplant team and the Principal Investigator.
• •Age \> 50 years, or if \< 50 years of age, considered to be at high risk for regimen-related toxicity associated with conventional myeloablative transplants due to pre-existing medical conditions or prior therapy.
• •A fully human leukocyte antigen (HLA)-identical sibling or matched unrelated donor is available. Potential participants with one antigen mismatched donors can be considered but only after discussion with the transplant team and the Principal Investigator.
• •Participant must be competent to give consent.